<DOC>
	<DOCNO>NCT00398112</DOCNO>
	<brief_summary>This phase II trial study well sunitinib work treat patient relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma . Sunitinib may stop growth cancer cell block enzymes need cell growth block blood flow cancer .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Relapsed Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess response rate ( complete response [ CR ] partial response ) patient relapse refractory chronic lymphocytic leukemia small lymphocytic lymphoma treat sunitinib malate . II . Assess toxicity drug patient . III . Assess duration response , time progression , overall survival , CR rate patient treat drug . SECONDARY OBJECTIVES : I . Evaluate know risk stratification parameter ( i.e. , immunoglobulin mutational status , ZAP-70 status , fluorescent situ hybridization [ FISH ] defect , and/or CD38 status ) relate clinical response sunitinib malate . OUTLINE : This multicenter study . Patients receive oral sunitinib malate daily day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients undergo blood collection periodically translational pharmacological study , include IgVH gene mutation status ZAP-70 status . Samples examine fluorescent situ hybridization ( FISH ) assay . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Diagnosis 1 follow : Biopsy proven small lymphocytic lymphoma ( SLL ) Chronic lymphocytic leukemia ( CLL ) meeting follow criterion : Peripheral blood lymphocyte count &gt; 5,000/mm^3 Lymphocytes must consist small moderate size lymphocyte , &lt; 55 % prolymphocytes , atypical lymphocyte , lymphoblast morphologically Immunophenotyping consistent CLL , define follow criterion : Predominant population lymphocyte share Bcell antigens ( i.e. , CD19 , CD20 , CD23 ) well CD5 absence panTcell marker ( e.g. , CD3 CD2 ) Dim surface immunoglobulin expression Exclusively kappa lambda light chain Splenomegaly , hepatomegaly , lymphadenopathy require Refractory relapsed disease evidence 1 follow criterion : Progression ≥ 1 course purine nucleoside ( i.e. , fludarabine phosphate , cladribine , pentostatin ) regimen Progression ≥ 1 course alkylator ( i.e. , cyclophosphamide chlorambucil ) regimen Relapse ≥ 1 prior purine nucleoside oral kylator ( i.e. , cyclophosphamide chlorambucil ) regimen Requires chemotherapy , indicate follow criterion : Measurable ( i.e. , &gt; 5,000/mm^3 ) progressive clonal lymphocytosis Measurable ( i.e. , single diameter &gt; 2 cm ) progressive lymphadenopathy Diseaserelated symptom , include 1 following : Weight loss &gt; 10 % within past 6 month Extreme fatigue attribute CLL/SLL Fevers &gt; 100.5^oF 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure , manifest development worsen anemia ( hemoglobin &lt; 10 g/dL ) and/or thrombocytopenia ( platelet count &lt; 100,000/mm^3 ) Massive ( i.e . &gt; 6 cm leave costal margin ) progressives plenomegaly No mantle cell lymphoma , demonstrate negative fluorescent situ hybridization ( FISH ) analysis fort ( 11 ; 14 ) ( IgVH/CCND1 ) peripheral blood tissue biopsy ECOG performance status 02 Life expectancy ≥ 12 month Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance ≥ 60 mL/min AST ALT ≤ 2.5 time ULN Bilirubin normal Alkaline phosphatase ≤ 3 time ULN Platelet count &gt; 30,000/mm^3 ( without transfusion ) Absolute neutrophil count &gt; 1,000/mm^3 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able complete patient diary alone assistance No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day No malignancy except squamous cell basal cell carcinoma skin situ carcinoma cervix , unless tumor curatively treat within past 2 year No history allergic reaction attribute compound similar chemical biological composition sunitinib malate No inability swallow retain sunitinib malate capsule due follow : Gastrointestinal tract disease Requirement IV alimentation Prior surgical procedure affect absorption Active peptic ulcer disease No preexisting thyroid abnormality would make patient unable maintain normal thyroid function medication No pulmonary embolism within past 12 month No serious nonhealing wound , ulcer , bone fracture No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Psychiatric illness social situation would limit compliance study requirement No cerebrovascular accident transient ischemic attack within past 12 month No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] ≥ 140 mm Hg diastolic BP ≥ 90 mm Hg ) No significant cardiac arrhythmia , include follow : QTc prolongation ( i.e. , QTc interval ≥ 500 msec ) Ventricular tachycardia Atrial fibrillation Atrial flutter Second third degree heart block No cardiac disease within past 12 month , include follow : Myocardial infarction Cardiac arrhythmia Stable/unstable angina Symptomatic congestive heart failure Coronary/peripheral artery bypass graft stenting No New York Heart Association ( NYHA ) class III IV heart failure The following patient eligible provided NYHA class II cardiac function baseline ECHO/MUGA : History NYHA class II heart failure asymptomatic treatment No prior anthracycline exposure No prior central thoracic radiation include heart radiation port See Disease Characteristics At least 4 week since prior chemotherapy At least 4 week since prior rituximab alemtuzumab At least 4 week since prior major surgery At least 4 week since prior oral steroid No prior treatment antiangiogenic agent , include follow : Bevacizumab Sorafenib Pazopanib AZD2171 Vatalanib VEGF Trap At least 7 day since prior concurrent CYP3A4 inhibitor , include follow : Ketoconazole Itraconazole Clarithromycin Erythromycin Diltiazem Verapamil HIV protease inhibitor ( i.e. , indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) Delavirdine At least 12 day since prior concurrent CYP3A4 inducer , include follow : Rifampin Rifabutin Carbamazepine Phenobarbital Phenytoin Hypericum perforatum ( St. John 's wort ) Efavirenz Tipranavir No concurrent investigational agent No concurrent agent proarrhythmic potential , include follow : Terfenadine Quinidine Procainamide Disopyramide Sotalol Probucol Bepridil Haloperidol Risperidone Indapamide Flecainide No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapies No concurrent therapeutic dos coumarinderivative anticoagulant ( e.g. , warfarin ) Concurrent prophylactic low molecular weight heparin warfarin dose ≤ 2 mg daily thrombosis prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>